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ABSTRACT The nuclear receptor steroidogenic fac-
tor-1 (SF-1, NR5A1) is a key regulator of adrenal and
gonadal biology. Disruption of SF-1 can lead to disor-
ders of adrenal development, while increased SF-1
dosage has been associated with adrenocortical tumor-
igenesis. We aimed to identify a novel subset of SF-1
target genes in the adrenal by using chromatin
immunoprecipitation (ChIP) microarrays (ChIP-on-chip)
combined with systems analysis. SF-1 ChIP-on-chip was
performed in NCI-H295R human adrenocortical cells
using promoter tiling arrays, leading to the identification
of 445 gene loci where SF-1-binding regions were located
from 10 kb upstream to 3 kb downstream of a transcrip-
tional start. Network analysis of genes identified as puta-
tive SF-1 targets revealed enrichment for angiogenic pro-
cess networks. A 1.1-kb SF-1-binding region was identified
in the angiopoietin 2 (Ang2, ANGPT2) promoter in a
highly repetitive region, and SF-1-dependent activation
was confirmed in luciferase assays. Angiogenesis is para-
mount in adrenal development and tumorigenesis, but
until now a direct link between SF-1 and vascular remod-
eling has not been established. We have identified Ang2 as
a potentially important novel target of SF-1 in the adrenal
gland, indicating that regulation of angiogenesis might be
an important additional mechanism by which SF-1 exerts
its actions in the adrenal gland.—Ferraz-de-Souza, B., Lin,
L., Shah, S., Jina, N., Hubank, M., Dattani, M. T., Acher-
mann, J. C. ChIP-on-chip analysis reveals angiopoietin 2
(Ang2, ANGPT2) as a novel target of steroidogenic fac-
tor-1 (SF-1, NR5A1) in the human adrenal gland. FASEB J.
25, 1166–1175 (2011). www.fasebj.org
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Steroidogenic factor-1 (SF-1, Ad4BP, encoded by
NR5A1) is a nuclear receptor transcription factor that
plays a central role in many aspects of adrenal and
reproductive development and function (1, 2). SF-1 is
expressed during early adrenal development in mice and
humans (3, 4), and disruption of SF-1 can be associated with
adrenal agenesis or hypoplasia in both species (5–10).
SF-1 is also emerging as a potentially important
regulator of adrenal tumor development (11). Somatic
duplication of the locus 9q33 that contains NR5A1 has
been reported in a high proportion of pediatric adre-
nal tumors on a background of TP53 loss of heterozy-
gosity (12). Overexpression of SF-1 transcript levels has
been reported in pediatric adrenal carcinoma (13),
and more recently, SF-1 protein expression was found
to be associated with poor clinical outcome in a large
cohort of adult adrenocortical carcinomas (14). These
data are supported further by studies of overexpression
of Sf-1 in the mouse, which results in adrenal cortical
cell proliferation and adrenal tumorigenesis (15).
Although many SF-1 target genes already have been
identified through detailed characterization of the pro-
moter and enhancer regions of known key factors (1),
it is likely that several other important SF-1 targets exist.
By using chromatin immunoprecipitation (ChIP) mi-
croarrays (ChIP-on-chip) combined with systems analy-
sis, we show that regulation of angiogenesis and vascu-
lar remodeling might be an important additional
mechanism by which SF-1 exerts its actions in endo-
crine development and tumorigenesis.
MATERIALS AND METHODS
ChIP
ChIP assays were performed using the ChIP-IT Express kit
(Active Motif, Rixensart, Belgium) following the manufac-
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turer’s instructions. NCI-H295R human adrenocortical tumor
cells were fixed with 1% formaldehyde and subsequently
sonicated in eight 20-s pulses at 2-m amplitude for 5 min
(MSE Soniprep 150; Sanyo Gallenkamp, Loughborough,
UK). Most resulting chromatin fragments ranged from 200 to
600 bp. Immunoprecipitation was performed in aliquots of
sheared chromatin from 2  106 cells using 3 g SF-1
antibody (07-618; Upstate Millipore UK Ltd., Watford, UK) or
2 g negative control IgG (ChIP-IT Control Kit–Human;
Active Motif; for ChIP-PCR only). Aliquots of sheared chro-
matin were separated to serve as input DNA control.
ChIP-on-chip analysis
Three independent ChIP assays were performed using Af-
fymetrix Human Promoter 1.0R Microarrays (Affymetrix UK
Ltd., High Wycombe, UK). SF-1-immunoprecipitated DNA
(50 ng), and respective input DNA were amplified by ligation-
mediated PCR, using a modified version of published proto-
cols (16, 17). In brief, chromatin was blunt-ended by 1 h
incubation at 37°C with T4 DNA Polymerase [New England
Biolabs (NEB) UK Ltd., Hitchin, UK] and 0.1 mM deoxyri-
bonucleotide triphosphate mix (dNTP; Bioline, London,
UK). Long (5-GCGGTGACCCGGGAGATCTGAATTC-3) and
short (5-GAATTCAGATC-3) unidirectional oligonucleotides
were heated to 100°C in a 50 mM NaCl solution and slowly
cooled to room temperature to generate double-stranded link-
ers, which were ligated to blunted chromatin overnight (16°C;
NEB T4 DNA Ligase). Linker-ligated chromatin was amplified
linearly by PCR using 0.1 U Taq polymerase, 3 M long oligonu-
cleotide, 1 M betaine, 2.5 mM MgCl2, and 0.1 mM dNTP dUTP
mix (25% dATP, 25% dCTP, 25% dGTP, 20% dTTP, and 5%
dUTP) and the following thermal cycling parameters: 1 cycle of
55°C for 2 min, 72°C for 5 min, and 95°C for 2 min; then 15 cycles
of 95°C for 30 s, 55°C for 30 s, and 72°C for 5 min; followed by a
4-min final extension at 72°C. Amplified DNA was fragmented and
end-labeled using the GeneChip WT Double-Stranded DNA Ter-
minal Labeling Kit, hybridized to GeneChip Human Promoter
1.0R arrays, and stained using the GeneChip Hybridization, Wash,
and Stain Kit (all Affymetrix).
Quality control of microarray data (3 SF-1-IP arrays, 3 input
DNA arrays) was performed using Affymetrix Tiling Analysis
Software and R/Bioconductor. Plotted histograms of the raw
data intensity suggested that enrichment by SF-1 IP was
suboptimal in one of the experiments, which was excluded
from final analysis.
The ChIP-on-chip peak detection tool cisGenome (18–20)
was used to define potential protein-binding regions. Quan-
tile normalization was applied prior to analysis, and a moving
average (MA) statistic was computed for each probe, based on
a half-window size of 300 bp or 5 probes. To increase
stringency, probes with the MA statistic 3.5 sd away from the
global mean were used to define protein-binding regions.
Peaks were discarded if they contained 5 probes or were
100 bp in width. Peaks that were separated by 300 bp or 5
probes were merged. Peaks that had a left-tail false discovery
rate 5% were discounted (18–20). The genomic coordi-
nates of all regions were converted into coordinates based on
U.S. National Center for Biotechnology Information (NCBI)
genome build 36 (hg18) and mapped to neighboring tran-
scriptional start sites (TSSs). Identified peaks were visualized
using the Integrated Genome Browser (IGB; ref. 21).
Confirmation of chromatin enrichment by PCR (ChIP-PCR)
SF-1-IP, IgG-IP, and 0.2% input DNA samples were used as
templates for PCR amplification of the promoters of the known
SF-1 targets CYP11A1 (22–25) and CITED2 (26, 27). Forward
and reverse primers were designed by Primer3 (28): CYP11A1
proximal promoter (100 bp upstream of TSS), forward 5-
AGAAATTCCAGACTGAACCTTCATA-3 and reverse 5-CTGT-
GACTGTACCTGCTCCACTTC-3 (198-bp long amplicon); and
CITED2 distal promoter (3.0 kb upstream of TSS), forward
5-CGGGAAACCACCAAAAGC-3 and reverse 5-AAGCAATG-
GCGAAAACTGTAA-3 (200-bp long amplicon). As a negative
control for SF-1 binding, primers amplifying exon 2 of PBX1
were used: forward 5-TGTTTTCACCCTGTGCATTATC-3 and
reverse 5-TAGATTTGTGACTGCTGGTTAAG-3 (223-bp long
amplicon). PCR reactions were performed with 0.4 M primers
and MegaMix (Microzone Ltd., Haywards Heath, UK) for 35
cycles of amplification with an annealing temperature of 55°C.
Promoter constructs
The 5.0-kb 5-upstream sequences of CITED2 (transcript
ENST00000367651, ENSEMBL release 54; NCBI build 36) and
ANGPT2 (transcript ENST00000325203, ENSEMBL release 54;
NCBI build 36) were analyzed for putative SF-1 binding sites
using MatInspector software (http://www.genomatix.de; ref.
29). Based on the position of predicted sites, the 3.3-kb,
900-bp, and 600-bp upstream sequences of the CITED2
promoter and the 4.5-, 1.9-, and 1.1-kb upstream sequences
of the ANGPT2 promoter were PCR amplified and individ-
ually cloned into a pGL4.10[luc2] luciferase reporter vec-
tor (Promega UK Ltd., Southampton, UK). For PCR am-
plification of these regions from genomic DNA, a 1:10
mixture of HotStarTaq DNA polymerase (Qiagen Ltd.,
Crawley, UK) and Platinum Pfx DNA polymerase (Invitro-
gen Ltd., Paisley, UK) was used, along with the following
thermal cycling parameters: initial denaturation at 95°C
for 15 min; 40 cycles of denaturation at 95°C for 20 s,
annealing at 55°C for 30 s, and extension at 68°C for 1
min/kb amplicon; and final extension at 68°C for 10 min.
Amplicons were TA cloned using the TOPO XL PCR
cloning kit (Invitrogen) and digested from pCR-XL-TOPO
vectors using KpnI and XhoI (NEB) to allow directional
cloning into pGL4.l0[luc2] vectors (ligation performed
overnight at 16°C with T4 DNA ligase; NEB). Expression
vectors (pCMX) containing SF-1 (NR5A1) [wild-type (WT)
and mutant G35E] cDNAs have been described previously
(8, 22).
Transient gene expression assays
Transient gene expression assays were performed in 96-well
plates using NCI-H295R cells, Lipofectamine 2000 (Invitro-
gen), and a dual-luciferase reporter assay system (Promega)
with cotransfection of pRLSV40 Renilla luciferase (7.5 ng/
well; Promega) as a marker of transfection efficiency. To
analyze the effects of SF-1 on CITED2 and ANGPT2 regulation
according to promoter length, individual pGL4.10-luc re-
porter constructs (100 ng/well) were cotransfected with
pCMXWT or mutant SF-1 expression vectors (50 ng/well).
Activation of the 4.5 kb ANGPT2 promoter by SF-1 was studied
further with increasing amounts of pCMXWT or mutant SF-1
expression vectors (10, 50, and 100 ng/well). Total DNA
transfected was kept constant. In all studies, cells were lysed
24 h after transfection and luciferase assays performed using
a FLUOstar Optima fluorescence microplate reader (BMG
Labtech, Aylesbury, UK). All data were standardized for
Renilla coexpression. Results are shown as means  se of 3
independent experiments, each performed in triplicate. Sta-
tistical analysis was performed using Student’s t tests.
Assessment of gene function and network analysis
MetaCore software (GeneGo Inc., St. Joseph, MI, USA;
http://www.genego.com) was used to investigate the func-
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tional annotations and potential network interactions of
genes identified as putative novel SF-1 targets from the
ChIP-on-chip analysis. Genes were selected based on the
criteria for protein-binding regions described above and
where the identified site was within 10 kb upstream and 3 kb
downstream of a recognized TSS. Only genes annotated by
the Human Genome Organization (HUGO) Gene Nomencla-
ture Committee (HGNC; http://www.genenames.org) were in-
cluded, and data were uploaded into GeneGo using unique
Entrez Gene ID identifiers. To determine which functional
categories and biological processes were enriched in the exper-
imental list of target genes, we used the Compare Experiments
workflow in GeneGo. Experimental targets were mapped onto
functional ontologies in MetaCore, in particular GeneGo Pro-
cess Networks, a set of 110 cellular and molecular processes
where content is defined and annotated by GeneGo. Gene
interaction networks were constructed using the Analyze Net-
works algorithm with default settings.
Immunohistochemistry of SF-1 and Ang2
Fetal adrenal tissue (fetal stage 1, 8 wk postconception) was
obtained from the Human Developmental Biology Resource
(HDBR, http://www.hdbr.org) with ethical review board ap-
proval and informed consent. Samples were embedded in
optimal cutting temperature (O.C.T.) compound and rapidly
frozen, and 14-m sections were obtained using an OTF5000
cryostat (Bright Instrument Co. Ltd., Huntingdon, UK).
Unfixed sections were air-dried for 2 h, immersed in ethanol
(	20°C) for 10 min, and stored at 	20°C. For immunostain-
ing, slides were thawed to room temperature and fixed for 3
min in 4% paraformaldehyde in PBS to preserve tissue
integrity with minimal increase in aldehyde-induced autofluo-
rescence. Samples were washed in 1% Tween 20 in Tris-
buffered saline (TBST), then blocked by 1 h incubation in
10% lamb serum in TBST. Simultaneous overnight incuba-
tion at 4°C was performed with the following primary anti-
bodies: mouse anti-human SF-1 (434200; Invitrogen; 1:200
dilution) and rabbit anti-human angiopoietin-2 (Ang2,
ANGPT2; ab65835; Abcam; 1:200 dilution). Slides were
washed and incubated overnight at 4°C in 10% lamb serum in
TBST with 4,6-diamidino-2-phenylindole (DAPI, 1 g/ml),
anti-mouse secondary antibody (Alexa647 goat anti-mouse,
A21235; Invitrogen; 1:400 dilution), and anti-rabbit second-
ary antibody (Alexa555 goat anti-rabbit; A21429; Invitrogen;
1:400 dilution). After washing, slides were mounted in
Vectashield (Vector Labs, Peterborough, UK) and imaged on
a LSM 710 confocal microscope (Carl Zeiss Ltd., Welwyn
Garden City, UK).
Figure 1. Validation of chromatin enrichment and correlation to transactivation studies. A) Chromatin enrichment was
confirmed by PCR amplification of the promoters of known SF-1 targets, CYP11A1 and CITED2, from anti-SF-1 immunopre-
cipitated DNA (SF-1) but not from anti-IgG immunoprecipitation (IgG). Exon 2 of PBX1, which is not expected to bear
SF-1-binding sites, was used as negative control. Cartoons show position of amplicons in relation to TSSs, which are represented
by arrows indicating start and direction of transcription (black bars represent exons). Inp, 0.2% input DNA. B) A SF-1-binding
region was identified by ChIP-on-chip in the CITED2 promoter, peaking at 2.9 kb upstream from the transcriptional start
(visualized using IGB; blue dotted line represents threshold for MA Z 3.5; white solid bar represents array coverage of CITED2
promoter). C) Top panel: cartoon representation of putative SF-1-binding sites (gray circles) identified by MatInspector in the
CITED2 promoter and their relation to the different reporter constructs studied (600 bp, 900 bp, and 3.3 kb in length). Bottom
panel: activation of different length CITED2 promoter constructs by SF-1 was investigated using luciferase assays. Consistent with
the prediction from ChIP-on-chip analysis, SF-1-dependent activation (black bars) of the 3.3-kb construct was greater than that
of the 900- and 600-bp constructs (P0.001). Open bars represent transfection with empty expression vector. Data are presented
as means  se of 3 independent experiments, each performed in triplicate (3.3 kbcontrol, P0.001; 900 bpcontrol,
P0.05; 600 bp, not significant).
Figure 2. Distribution of SF-1-binding regions neighboring
TSSs. A greater density of SF-1-binding sites is observed 2.5
kb upstream (	) and 1.5 kb downstream () of TSSs, with
peaks  1 sd from the mean. Solid line represents a 2-point
moving average for the data set.
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TABLE 1. Top-ranking SF-1-binding regions located from 10 kb upstream to 3 kb downstream of a TSS
MA Z
score Chr Start End
Region
length
(bp)
Distance
to TSS
(bp) Gene Gene name
Selected GO biological
process/molecular function
8.02 19 61052876 61053237 362 	2142 NLRP4 NLR family, pyrin domain
containing 4
ATP binding; nucleotide
binding; protein binding
7.26 4 606174 606996 823 	2787 PDE6B Phosphodiesterase 6B,
cGMP-specific, rod, 

Detection of light stimulus;
response to stimulus;
signal transduction
7.22 3 8671294 8671558 265 	2690 C3orf32 Chromosome 3 open
reading frame 32
Mouse: protein folding; heat
shock protein binding
7.14 13 113199316 113199973 658 	6621 DCUN1D2 DCN1, defective in cullin
neddylation 1, domain
containing 2 (Saccharomyces
cerevisiae)
6.81 9 99502264 99502676 413 	3011 XPA Xeroderma pigmentosum,
complementation group A
DNA damage removal;
signal transduction
resulting in induction of
apoptosis; response to
oxidative stress
6.51 15 20377626 20377881 256 	7189 TUBGCP5 Tubulin,  complex
associated protein 5
Microtubule cytoskeleton
organization;
microtubule nucleation
6.17 13 113367394 113368774 1381 	7583 ATP4B ATPase, H/K
exchanging, 
 polypeptide
Ion transport; ATP
biosynthetic process;
response to
lipopolysaccharide
	1513 GRK1 G-protein-coupled receptor
kinase 1
Positive regulation of
phosphorylation; signal
transduction; apoptosis
6.12 3 8672091 8672356 266 	3487 C3orf32 Chromosome 3 open
reading frame 32
Mouse: protein folding;
heat shock protein
binding
5.84 14 92455627 92456518 892 	3172 CHGA Chromogranin A
(parathyroid secretory
protein 1)
Regulation of blood
pressure; protein binding
5.78 19 3123496 3123904 409 	6065 S1PR4 Sphingosine-1-phosphate
receptor 4
G-protein-coupled receptor
protein signaling
pathway; elevation of
cytosolic calcium ion
concentration
5.61 8 6411196 6412323 1128 	3588 ANGPT2 Angiopoietin 2 Angiogenesis; blood vessel
morphogenesis;
multicellular organismal
development
5.49 13 113149179 113149920 742 1908 ADPRHL1 ADP-ribosylhydrolase like 1 Protein amino acid
de-ADP-ribosylation;
magnesium ion binding
5.49 19 40729390 40729965 576 1293 TMEM147 Transmembrane protein 147 Protein binding
5.36 2 183644509 183645199 691 	6877 DUSP19 Dual specificity phosphatase
19
Protein amino acid
dephosphorylation;
inactivation of MAPK
activity; JNK cascade
5.30 7 43878032 43878592 561 	2643 MRPS24 Mitochondrial ribosomal
protein S24
Translation; structural
constituent of ribosome
5.24 9 110664647 110665656 1010 	7121 ACTL7B Actin-like 7B Protein binding; structural
constituent of
cytoskeleton
728 ACTL7A Actin-like 7A Protein binding; structural
constituent of
cytoskeleton
(continued on next page)
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RESULTS
Validation of chromatin enrichment and characterization
of SF-1-dependent regulation of CITED2
ChIP with the anti-SF-1 antibody was performed in
NCI-H295R human adrenocortical tumor cells. To val-
idate chromatin enrichment by this anti-SF-1 antibody,
ChIP-PCR assays were performed using primers located
in the promoters of the known SF-1 targets, CYP11A1
(22–25) and CITED2 (refs. 26, 27 and Fig. 1A). Primers
located around exon 2 of PBX1 were used as a negative
control for SF-1 binding, as this region does not contain
SF-1-binding sites. The promoter regions of CYP11A1
and CITED2 were amplified from SF-1-immunoprecipi-
tated DNA, confirming chromatin enrichment by ChIP,
whereas exon 2 of PBX1 failed to amplify. In addition,
specificity of immunoprecipitation with the anti-SF-1
TABLE 1. (continued)
MA Z
score Chr Start End
Region
length
(bp)
Distance
to TSS
(bp) Gene Gene name
Selected GO biological
process/molecular function
5.21 22 22563867 22564131 265 	2565 MIF Macrophage migration
inhibitory factor
(glycosylation-
inhibiting factor)
Positive regulation of ERK1
and ERK2 cascade;
negative regulation of
apoptosis
5.19 21 44030889 44031745 857 	2541 RRP1 Ribosomal RNA
processing 1 homolog
(S. cerevisiae)
rRNA processing
5.14 9 130885372 130885644 273 2282 DOLPP1 Dolichyl pyrophosphate
phosphatase 1
Protein amino acid
N-linked glycosylation;
catalytic activity
5.12 7 43881830 43882948 1119 	6720 MRPS24 Mitochondrial ribosomal
protein S24
Translation; structural
constituent of ribosome
5.08 2 121263371 121263617 247 	2832 GLI2 GLI family zinc finger 2 Mammary gland
development; positive
regulation of
transcription;
developmental growth;
transcription factor
activity
5.08 3 12804229 12804769 541 	8671 CAND2 Cullin-associated and
neddylation-dissociated
2 (putative)
Regulation of
transcription;
transcription activator
activity; TATA-binding
protein binding
5.07 3 48450915 48451316 402 	9370 PLXNB1 Plexin B1 Multicellular organismal
development;
intracellular signaling
pathway
	5574 CCDC72 Coiled-coil domain
containing 72
5.07 9 139889204 139889711 508 	2604 CACNA1B Calcium channel,
voltage-dependent,
N type,  1B subunit
Calcium ion transport;
transmembrane
transport; voltage-gated
calcium channel activity
5.06 15 38971991 38972237 247 	1805 VPS18 Vacuolar protein sorting
18 homolog (S.
cerevisiae)
Protein transport;
endosome organization
5.05 15 73417958 73418364 407 	8301 NEIL1 Nei endonuclease
VIII-like 1 (Escherichia
coli)
DNA repair; metabolic
process; negative
regulation of nuclease
activity
2735 COMMD4 COMM domain
containing 4
Protein binding
5.04 7 43924834 43926219 1386 	7045 UBE2D4 Ubiquitin-conjugating
enzyme E2D 4
(putative)
Regulation of protein
metabolic process;
post-translational protein
modification
Chromosomal coordinates (NCBI human genome build 36) and length of anti-SF-1 immunoprecipitated regions meeting criteria of an MA
Z score 5.0 are shown. For each binding region, distances to the TSSs of neighboring genes are specified (negative if upstream of TSS; positive
if downstream of TSS). Selected gene ontology (GO) annotation, when available, is also provided. Chr, chromosome.
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antibody was confirmed by the absence of amplification
of these promoters from immunoprecipitated chroma-
tin when IgG was used for ChIP.
Following validation, SF-1 ChIP-on-chip analysis was
performed using single-tiling promoter arrays (Ge-
neChip Human Promoter 1.0R arrays) and genomic
DNA (input chromatin) as hybridization control. ChIP-
on-chip analysis identified a SF-1-binding region in the
CITED2 promoter (Chr6:139,739,907–139,740,330; NCBI
genome build 36) peaking at 2.9 kb upstream from the
TSS (Chr6:139,737,478; NCBIv36) with an MA Z score of
4.44 (Fig. 1B). Using MatInspector software to analyze the
5.0-kb upstream sequence of CITED2, 4 putative SF-1
binding sites were identified at 3080, 1247, 665, and 458
bp upstream of the TSS (Fig. 1C). To verify SF-1-respon-
siveness of the binding site identified by ChIP-on-chip,
reporter constructs containing different lengths of the
CITED2 promoter were designed, and activation by SF-1
was studied in luciferase assays. Activation of a 3.3-kb
CITED2 promoter construct by SF-1 was greater than that
of the 900- and 600-bp promoter constructs, in keeping
with the ChIP-on-chip results (Fig. 1C).
Identification of novel SF-1-binding sites by
ChIP-on-chip
Analysis of ChIP-on-chip experiments with CisGenome
identified 738 SF-1-binding regions that met criteria of an
MA score  3.5 mean  sd and a false discovery rate of
5%. Subsequent analysis focused on those regions that
were located between 10 kb upstream and 3 kb down-
stream of the TSS of known genes (as defined by HGNC),
in keeping with the design of the Human Promoter 1.0R
arrays. Using this approach, binding regions were anno-
tated to 445 gene loci (Supplemental Tables 1A, B). The
distribution of immunoprecipitated sequences revealed
greater density of SF-1-binding sites around 2.5 kb up-
stream and 1.5 kb downstream of TSSs (Fig. 2).
Binding regions surrounded the TSS of 397 unique
genes. More than one SF-1-binding site was identified in
the defined 	10 kb  TSS  3 kb region of 35 genes:
of these, 27 genes had 2 binding sites, 4 genes had 3, 3
genes had 4, and 1 gene had 5 SF-1-binding sites. Top-
ranking TSS-neighboring binding sites (MA Z5.0) are
detailed in Table 1.
Figure 3. SF-1 binding on the ANGPT2 promoter. A) ChIP-
on-chip identified a 1.1-kb SF-1-binding region in the pro-
moter region of ANGPT2 (encoding Ang2) located from 3.0
to 4.1 kb upstream of the TSS (visualized using IGB; blue
dotted line represents threshold for MA Z  3.5; white solid
bar represents array coverage of the ANGPT2 promoter).
B) Accordingly, in silico analysis of the upstream sequence of
ANGPT2 with MatInspector identified 20 putative SF-1 bind-
ing sites (highlighted in gray), 18 of which clustered in a
highly repetitive region between 3.1 to 4.1 kb upstream of the
TSS [transcribed sequence shown in bold and underscored;
transcript ENST00000325203, ENSEMBL release 54; (NCBI
build 36)].
TABLE 2. Comparison of experimentally identified SF-1 targets
to published adrenocortical tumor expression datasets
MA Z score SF-1 target
Giordano
et al. (31)
West
et al. (30)
Soon
et al. (32)
5.61 ANGPT2   
4.79 SHMT2 
4.58 YKT6  
3.84
4.74 TBRG4 
4.18 SLC31A2 
4.07 PCSK6  
3.97 SPARC 
3.96 RGS3 
3.83 KPNA4 
3.76 TSPAN17 
3.73 DOLK 
3.70 ATAD2 
3.68 CREB5 
3.65 LPCAT4 
3.63 NR6A1 
3.55 CDC20 
3.54 KIF3C 
ChIP-identified SF-1 targets that have been found to be
overexpressed in adrenocortical carcinomas in comparison to
adenomas (31, 32) and in pediatric adrenocortical tumors in
general (30). Two independent SF-1 binding regions were identi-
fied at the YKT6 gene loci. Ang2 (ANGPT2) emerged as the
common factor in all datasets.
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Ang2 (ANGPT2) as a target of SF-1
To identify potential networks of target genes being
regulated by SF-1, the gene loci dataset was analyzed
using the MetaCore platform of GeneGo systems biol-
ogy software. Although several potential gene interac-
tion networks focused on established nuclear receptor
systems (e.g., Supplemental Figs. S1 and S2), enrich-
ment analysis revealed that experimental targets
mapped to process networks related to blood vessel
morphogenesis (P0.002) and regulation of angiogen-
esis (P0.027). ChIP-on-chip-identified SF-1 targets in-
volved in such process networks included ADORA3,
ANGPT2, CXCR4, GLI2, HTR1A, PLCD1, S100A7, SP1,
and SPARC, among others.
Considering that ChIP-on-chip experiments were per-
formed on an adrenocortical tumor cell line and that SF-1
might play an important role in adrenal tumorigenesis,
experimentally identified SF-1 targets were compared to
published datasets of adrenocortical tumor gene expres-
sion in children (30) and adults (refs. 31, 32 and Table 2).
Ang2 (encoded by ANGPT2; MIM 601922) emerged as a
common factor in all these datasets and within a GeneGo
angiogenic process network.
Characterization of ANGPT2 regulation
The SF-1-binding region identified in the ANGPT2 pro-
moter by ChIP-on-chip spans 1.1 kb from Chr8:6,411,196
to Chr8:6,412,323 (NCBIv36), with an MA Z score of 5.61
(Fig. 3A). Since the TSS of ANGPT2 is at Chr8:6,408,174
(in the reverse strand) in that genome assembly, ChIP-on-
chip data predicted the binding region to be located from
3.0 to 4.1 kb upstream of the TSS. Analysis of the 5.0-kb
upstream sequence of ANGPT2 with MatInspector identi-
fied 20 putative SF-1 binding sites, 18 of which clustered in
a highly repetitive region between 3.1 to 4.1 kb upstream
of the TSS, in accordance with the experimental data
(Fig. 3B). To confirm these findings, reporter vectors
containing variable lengths of the ANGPT2 promoter (1.1,
1.9, and 4.5 kb) were constructed, and activation by SF-1
in NCI-H295R human adrenal cells was assessed by lu-
ciferase assays. Shorter promoter fragments (1.1 and 1.9 kb)
were not activated by WT SF-1 (Fig. 4A), whereas dose-
dependent activation of the 4.5 kb ANGPT2 pro-
moter construct was seen (Fig. 4B). This activation
was lost when the functionally impaired G35E mutant
SF-1 construct was used.
SF-1 and Ang2 expression during early human fetal
adrenal development
To investigate the potential coexpression of SF-1 and
Ang2 in a biologically relevant system, immunohisto-
chemistry was performed using human fetal adrenal
tissue (fetal stage 1, 8 wk postconception). This is a
stage of rapid adrenal development and growth, as well
as the onset of steroidogenesis (33). Strong nuclear
expression of SF-1 was seen in the developing definitive
zone, with less intense staining of a subset of cells within
the fetal cortex (Fig. 5). Ang2 expression was observed
in the cytoplasm of cells and extracellular space, pre-
dominantly in the definitive zone and subcapsular
region and around areas of strong SF-1 expression.
Figure 4. SF-1-dependent regulation of ANGPT2. A) Top panel: cartoon representation of putative SF-1-binding sites (gray
circles) identified by MatInspector in the ANGPT2 promoter in relation to the 3 different length reporter constructs studied
(1.1, 1.9, and 4.5 kb). Bottom panel: pGL4 reporter vectors containing variable lengths of the ANGPT2 promoter (or empty, for
background assessment) were cotransfected into NCI-H295R human adrenal cells with either WT SF-1 (WT), mutant SF-1 (Mut)
or empty (	) expression vectors 24 h prior to luciferase assays. While shorter promoter fragments (1.1 and 1.9 kb) failed to be
activated by SF-1, the 4.5-kb ANGPT2 promoter construct was activated by the WT protein (P0.05 vs. empty).
B) Dose-dependent activation of the 4.5-kb ANGPT2 by WT SF-1 was not observed when the functionally impaired G35E mutant
SF-1 construct was used (means  se of 3 independent experiments, each performed in triplicate).
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DISCUSSION
SF-1 is a key regulator of adrenal development and
cancer, and angiogenesis is important in these processes;
however, until now a direct link between SF-1 and
vascular remodeling has not been established. By using
a combination of ChIP-on-chip, network analysis, ex-
pression data, and functional genomic studies, we have
identified Ang2 (ANGPT2) as a potentially important
novel target of SF-1 in the adrenal gland.
Angiopoietins are secreted ligands for the tyrosine
receptor kinase Tie2 that act in concert with vascular
endothelial growth factor (VEGF, mainly VEGF-A) to
regulate angiogenic remodeling (34). While Ang1, the
first identified Tie2 ligand, acts toward stabilizing vessel
walls, Ang2 has a central role in destabilizing vascula-
ture so that regression (in the absence of VEGF) or
angiogenic sprouting (in presence of VEGF) can occur.
Ang2 is widely expressed in the endothelium during
developmental stages and in sites of active vascular
remodeling such as the placenta, ovaries and uterus
(34). VEGF and Ang2 are key regulators in tumor
angiogenesis, facilitating tumor growth and metastasis,
and overexpression of Ang2 has been documented in
many tumor types (e.g., liver, renal, gastric, breast,
colon, pancreas, lung; refs. 35, 36). Consistent with this,
a higher Ang2:Ang1 ratio correlates with worse prog-
nosis for many cancers (36).
Angiogenesis and vascular remodeling are also impor-
tant in the development of endocrine tissues, including
the adrenal gland. Although these systems are not as well
studied as tumorigenesis, recent work by Jaffe and col-
leagues (37, 38) has shown a preponderance of subcap-
sular angiogenesis during human fetal adrenal develop-
ment (14 to 22 wk postconception) and has reported that
adrenocorticotropin (ACTH)-driven zonal differential ex-
pression of Ang2 is an important part of this process. In
those studies, it was proposed that local factors would
mediate the angiogenic response to tropic stimuli during
fetal adrenal development, and up-regulate ANGPT2 in
the definitive zone of the fetal gland. Our results now
suggest a direct interaction of SF-1 in binding to and
activating the ANGPT2 promoter. Furthermore, we dem-
onstrate that SF-1 and Ang2 are strongly coexpressed in
the subcapsular region and developing definitive zone of
the human fetal adrenal gland at a critical early stage of
development, namely 8 wk postconception. Considering
that the architectural arrangement of blood vessels in the
adrenal cortex is such that nearly every adrenocortical cell
is thought to lie adjacent to a vascular endothelial cell
(39), SF-1-dependent Ang2 expression in adrenocortical
cells could be postulated to act in a paracrine way and
coordinate vascular remodeling in the developing adre-
nal. This is supported by findings of abnormal adrenocor-
tical vasculature in adult Sf-1 haploinsufficient mice (40).
Even though a role for SF-1 in regulating angiogenesis
Figure 5. SF-1 and Ang2 expression during early human fetal adrenal development. Top panel: immunohistochemistry for SF-1
and Ang2 in the human fetal adrenal gland (fetal stage 1, 8 wk postconception) shows strongest expression of these factors in
the developing definitive zone (DZ). FZ, fetal zone. Nuclear staining is shown with DAPI. Bottom panel: higher-power
magnification shows coexpression of SF-1 and Ang2 in areas of the definitive zone.
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has not yet been described, members of the related NR4A
nuclear receptor subfamily have recently been recognized
as important regulators of vascular gene expression, play-
ing critical roles in many aspects of vascular biology (41).
In particular, NR4A1 (Nur77, NGFI-B) has been shown to
drive the transcription of the plasminogen activator inhib-
itor 1 (PAI-1) in human umbilical vein endothelial cells
(42) and to act as a transcriptional mediator for VEGF-A-
induced angiogenesis, with distinct proangiogenic effects
in vivo (43). Interestingly, up-regulation of NR4A1 was
proposed by Bland et al. (44) as a compensatory mecha-
nism for maintaining transcriptional regulation of steroid-
ogenesis in Sf-1 haploinsufficient mice. Considering the
crossover in the regulatory spectra of these related nuclear
receptors, a role for SF-1 itself in the regulation of adrenal
vascular biology is further supported.
The link between developmental processes and tumori-
genesis is not novel and an increasing number of examples
are being reported in the endocrine and genetic literature.
In some cases, loss of function changes in key transcriptional
regulators or signaling pathways results in hypoplasia of
developing glands and hormone deficiency syndromes.
Conversely, overactivity or increased expression of these
factors and/or pathways has been associated with tumorigen-
esis. This is the case for the thyroid transcription factor-1
(TTF-1, encoded by NKX2–1; refs. 45, 46) and the thyrotro-
pin receptor (TSHR; refs. 47, 48) in the thyroid and for
the luteinizing hormone/choriogonadotropin receptor
(LHCGR) in the testis (49, 50). While mitogenic processes
might be the key drive in many of these events, the regula-
tion of angiogenesis and vascular remodeling is now emerg-
ing as an important additional mechanism.
Taken together, our data provide insight into additional
mechanisms by which SF-1 might regulate adrenal develop-
ment during fetal life. Although these studies were per-
formed predominantly in an adrenal carcinoma-derived cell
line, our results might be relevant to the pathophysiological
mechanisms promoting adrenal tumorigenesis following so-
matic SF-1 overexpression.
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